Daniel Laroche, MD
Ophthalmology · New York, NYNPI 1841225786
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Sight Sciences, Inc. at 35.2% of the total. Reporting peaked in 2020 at $24,065 and has fallen 95.5% since, to $1,076 in 2025. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $468.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$26K
- Aerie Pharmaceuticals, Inc.$20K
- Ivantis, Inc$18K
- Johnson & Johnson Surgical Vision, Inc.$3K
- Alcon$3K
- Nidek CO., LTD.$2K
- plus $4K from 20 others
Across 3 payments — averaging $25,651 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$75K
- Nidek CO., LTD.$2K
What the payments were for
- Consulting fees$27,01436%
- Speaking & faculty fees$37,44051%
- Travel & lodging$8101%
- Food & beverage$8,69312%
- Education$800%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 25 | $26,039 |
| Aerie Pharmaceuticals, Inc. | 26 | $19,555 |
| Ivantis, Inc | 13 | $17,848 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $2,702 |
| Alcon | 25 | $2,623 |
| Nidek CO., LTD. | 1 | $1,500 |
| AbbVie(2 entities) | 11 | $816 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $721 |
| Sun Pharmaceutical Industries Inc. | 5 | $422 |
| NEW World Medical,inc. | 6 | $269 |
| Bausch & Lomb Americas Inc. | 7 | $264 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $192 |
| Glaukos Corporation | 2 | $145 |
| Genentech USA, Inc. | 1 | $125 |
| Novartis | 2 | $122 |
| Kala Pharmaceuticals, Inc. | 1 | $119 |
| Gilead | 1 | $119 |
| Pfizer | 1 | $109 |
| Rxsight Inc | 1 | $94 |
| Oyster Point Pharma, Inc. | 2 | $58 |
| Thea Pharma Inc. | 2 | $49 |
| Carl Zeiss Meditec USA, Inc. | 2 | $44 |
| Amgen | 2 | $40 |
| Tarsus Pharmaceuticals, Inc. | 1 | $32 |
| Ocular Therapeutix, Inc. | 2 | $30 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$20,354
- Rocklatan$20,354
- Hydrus$17,376
- OMNI(R) SURGICAL SYSTEM (US)$14,734
- OMNI$10,625
- Tecnis Simplicity$1,941
- VYZULTA$770
- Hydrus Microstent$639
- Clareon$444
- Tecnis IOL$414
- CEQUA$371
- XEN GLAUCOMA TREATMENT SYSTEM$248
- SIMBRINZA$148
- VERITAS Vision System$141
- XEN$136
- Ahmed Glaucoma Valve$131
- Kahook Dual Blade$131
- VABYSMO$125
- INVELTYS$119
- Livdelzi$119
How this compares
$74,057 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 90 | $69,092 |
| RhopressaNetarsudil Mesylate | 95 | $42,273 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 163 | $42,103 |
| Brimonidine Tartrate | 321 | $28,781 |
| Prednisolone Acetate | 493 | $26,413 |
| RocklatanNetarsudil Mesylat/Latanoprost | 53 | $26,281 |
| CombiganBrimonidine Tartrate/Timolol | 59 | $25,447 |
| LumiganBimatoprost | 33 | $18,772 |
| Latanoprost | 1,292 | $14,339 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 741 | $9,799 |
| Ketorolac Tromethamine | 466 | $9,622 |
| Pilocarpine Hcl | 171 | $7,962 |
| Ofloxacin | 375 | $6,408 |
| Alphagan PBrimonidine Tartrate | 16 | $6,339 |
| Travoprost | 30 | $4,335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan, Alphagan P | $816 | $119,651198 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $19,555 | $68,554148 claims |
| AlconSimbrinza | $2,623 | $42,103163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
- Michael CooneyNew York$398K
- David GuyerNew York$322K
- Ashley BrissetteNew York$315K
- Jason SlakterNew York$272K
- David ChuNew York$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.